Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer
Editat de Mohammad Resa Nowrousianen Limba Engleză Paperback – 23 aug 2016
Preț: 733.05 lei
Preț vechi: 771.62 lei
-5% Nou
Puncte Express: 1100
Preț estimativ în valută:
140.28€ • 147.11$ • 116.98£
140.28€ • 147.11$ • 116.98£
Carte tipărită la comandă
Livrare economică 07-21 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9783709119044
ISBN-10: 3709119049
Pagini: 866
Ilustrații: XVIII, 866 p.
Dimensiuni: 168 x 240 mm
Greutate: 1.38 kg
Ediția:Softcover reprint of the original 2nd ed. 2008
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
ISBN-10: 3709119049
Pagini: 866
Ilustrații: XVIII, 866 p.
Dimensiuni: 168 x 240 mm
Greutate: 1.38 kg
Ediția:Softcover reprint of the original 2nd ed. 2008
Editura: SPRINGER VIENNA
Colecția Springer
Locul publicării:Vienna, Austria
Cuprins
Physiology of erythropoiesis.- Biology of EPO and EPO-receptor.- The role of erythropoietin receptor expression on tumor cells.- Problems associated with erythropoietin receptor determination on tumor cells.- Definition, classification and characterization of anemia in cancer.- Pathophysiology of anemia in cancer.- Prevalence and incidence of anemia and risk factors for anemia in patients with cancer.- Significance of anemia in cancer chemotherapy.- Incidence and impact of anemia in radiation oncology.- Relationship between hemoglobin levels and tumor oxygenation.- Tumor hypoxia and therapeutic resistance.- Symptoms of anemia.- Impact of anemia and red blood cell transfusion on organ function.- Relationship of hemoglobin, fatigue, and quality of life in anemic cancer patients.- When to use red blood cell transfusions in cancer patients with solid tumours?.- Pharmacology, pharmacokinetics and safety of recombinant human erythropoietin preparations.- Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma.- rhEPO in anemic patients with solid tumors and chemotherapy — efficacy and safety.- Early intervention with recombinant human erythropoietin for chemotherapy-induced anemia.- Recombinant human erythropoietin (rhEPO) therapy in myelodysplasia.- Prediction of response to rhEPO in the anemia of cancer.- rhEPO in hematopoietic stem cell transplantation.- Treatment of anemia with rhEPO in radiation oncology.- Recombinant human erythropoietin in pediatric oncology.- rhEPO in surgical oncology.- Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy.- Are there risks for use of iron in cancer patients?.- Metabolic and physiologic effects of rhEPO in anemic cancer patients.- Effects of rhEPO on quality of lifein anemic cancer patients.- Thrombosis during therapy with erythropoiesis stimulating agents in cancer.- The effect of rhEPO on survival in anemic cancer patients.- From bench to bedside: Neuroprotective effects of erythropoietin.- rhEPO in patients with anemia and congestive heart failure.- Cost-effectiveness of treating cancer anaemia.
Caracteristici
Comprehensive presentation of anemia in cancer and its treatment Assessment of current and potential applications of erythropoietin Presented by world experts in the field Includes supplementary material: sn.pub/extras